These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 17300567

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [Abstract] [Full Text] [Related]

  • 4. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group.
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [Abstract] [Full Text] [Related]

  • 5. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM.
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study.
    Pece A, Isola V, Vadalà M, Matranga D.
    Retina; 2006 Sep; 26(7):746-51. PubMed ID: 16963846
    [Abstract] [Full Text] [Related]

  • 10. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
    Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES.
    Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388
    [Abstract] [Full Text] [Related]

  • 11. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK, Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA.
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [Abstract] [Full Text] [Related]

  • 12. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration.
    Voelker M, Gelisken F, Ziemssen F, Wachtlin J, Grisanti S.
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1241-6. PubMed ID: 16010552
    [Abstract] [Full Text] [Related]

  • 13. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA, Tewari A.
    Retina; 2006 Dec; 26(9):988-93. PubMed ID: 17151484
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
    Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
    Arch Ophthalmol; 2002 Oct; 120(10):1307-14. PubMed ID: 12365909
    [Abstract] [Full Text] [Related]

  • 16. Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV.
    Wachtlin J, Stroux A, Wehner A, Heimann H, Foerster MH.
    Graefes Arch Clin Exp Ophthalmol; 2005 May; 243(5):438-45. PubMed ID: 15672299
    [Abstract] [Full Text] [Related]

  • 17. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
    Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
    Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
    [Abstract] [Full Text] [Related]

  • 18. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R, Gabric N.
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [Abstract] [Full Text] [Related]

  • 19. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
    Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G, Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group, Verteporfin in Photodynamic Therapy study group.
    Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
    [Abstract] [Full Text] [Related]

  • 20. Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration.
    Michels S, Wachtlin J, Gamulescu MA, Heimann H, Prünte C, Inhoffen W, Krebs I, Schmidt-Erfurth U.
    Ophthalmology; 2005 Dec; 112(12):2070-5. PubMed ID: 16225928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.